W
WAVEMAN · COMPANY
MGTX · Meiragtx Holdings Plc
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

MGTX

MeiraGTx Holdings plc
PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001735438
FORM 144 · 3☆ WATCH
INSIDER NET · 180D
-$3.8M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
118
13F, latest reported quarter
REVENUE GROWTH
+144.6%
XBRL, annual
NET MARGIN
-140.3%
CONVERSIONS · 180D
1
codes C/M, not in net · no price filed
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$3.8M over 180 days
-$2.0M over 90 days
below 76% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
118 funds added or opened last quarter
more than 71% of Pharma & Biotech
REVENUE
+144.6% year over year
more than 87% of Pharma & Biotech
MARGIN
-140.3% net margin
below 68% of Pharma & Biotech
BUYBACKS
$18.2M repurchased, FY to 2026-06-30
below 62% of Pharma & Biotech
SHORT
4.1% of shares outstanding short · 8.3 days to cover · settled 2026-07-31
below 51% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$3.8M across 3 people in 180 days.
118 funds added or opened positions in the latest 13F quarter, of 159 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +90.3%
+90.3%12M
-4%+32%+69%+105%2025-092025-102025-122026-032026-052026-072026-09 2026-08-18 · Forbes Alexandria sold $859.3K2026-07-21 · Giroux Richard sold $700.6K2026-04-21 · Giroux Richard sold $572.3K2026-05-19 · Forbes Alexandria sold $568.5K2026-03-24 · Forbes Alexandria sold $459.4K2025-10-07 · Forbes Alexandria sold $398.5K2026-07-07 · Naylor Stuart sold $374.2K2026-04-07 · Naylor Stuart sold $258.9K2025-10-21 · Giroux Richard sold $212.9K2026-07-07 · Naylor Stuart sold $35.3K2026-08-18 · Alexandria Forbes filed to sell $859.3K2026-07-21 · Richard Giroux filed to sell $700.6K2026-07-07 · Naylor Stuart filed to sell $368.7K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $3.8M sold by insiders over 180 days, 118 funds added last quarter, $1.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, MeiraGTx Holdings plc insiders sold a net $3.8M of stock across 33 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Forbes Alexandria
PRESIDENT & CEO
SELL
2026-08-18
62,000.0
$859.3K
Giroux Richard
CFO & COO
SELL
2026-07-21
56,000.0
$700.6K
Naylor Stuart
CHIEF SCI OFCR, OPHTHALMOLOGY
SELL
2026-07-07
2,547.0
$35.3K
Naylor Stuart
CHIEF SCI OFCR, OPHTHALMOLOGY
SELL
2026-07-07
25,112.0
$374.2K
Forbes Alexandria
PRESIDENT & CEO
SELL
2026-05-19
62,000.0
$568.5K
33 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 28 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Sanofi
12,197,737.0 sh
$164.8M
PERCEPTIVE ADVISORS LLC
10,786,658.0 sh
$145.7M
Rubric Capital Management LP
9,100,000.0 sh
$122.9M
JOHNSON & JOHNSON
6,641,064.0 sh
$89.7M
BlackRock, Inc.
4,757,178.0 sh
$64.3M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Alexandria Forbes
FILED 2026-08-18
$859.3K
Richard Giroux
FILED 2026-07-21
$700.6K
Naylor Stuart
FILED 2026-07-07
$368.7K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
AlphaCentric Life Sciences and Healthcare Fund
$465.0K POSITION · AS OF 2026-03-31
1.2%
Invesco NASDAQ Future Gen 200 ETF
$60.2K POSITION · AS OF 2026-02-28
0.4%
NORTH SQUARE KENNEDY MICROCAP FUND
$121.9K POSITION · AS OF 2026-02-28
0.4%
Eventide Small Cap ETF
$27.5K POSITION · AS OF 2026-04-30
0.1%
Invesco Nasdaq Biotechnology ETF
$33.9K POSITION · AS OF 2026-02-28
0.0%
Small Cap Core Fund
$77.9K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$8.3M
$11.8M
$4.9M
+21%
2024
$6.9M
$6.1M
$4.4M
-7%
2023
$6.3M
$5.8M
$3.7M
+8%
2022
$7.7M
-$1.1M
$5.3M
-73%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$81.4M$33.3M$14.0M$15.9M
OPERATING INCOME$-106.0M$-164.2M$-137.1M$-116.4M
NET INCOME$-114.2M$-147.8M$-84.0M$-129.6M
EPS (DILUTED)-1.42-2.12-1.49-2.87
OPERATING CASH FLOW$-46.4M$-104.5M$-105.4M$-73.1M
CASH$65.9M$103.7M$129.6M$115.5M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →